English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 October 2018, 07:00 HKT/SGT
Share:
        

Source: Novotech Health Holdings Pte Ltd / Clinical Network Services (CNS)
Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Asia-Pacific CRO Novotech has acquired Australasian specialist CRO Clinical Network Services (CNS), with a mutual mission to expand services

SYDNEY, AU, Oct 19, 2018 - (ACN Newswire) - Novotech, the largest Asia-Pacific-based CRO, has acquired Australasian specialist CRO Clinical Network Services (CNS), as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials. Both companies will continue to retain their separate brands and identities.

Early phase CNS clients, wishing to advance into later phase regional trials, can tap into Novotech's Asia-Pacific expertise backed by 10 partnership agreements with leading hospitals and medical institutions, offering access to 1.4 billion people living in urban areas across the region. Novotech has 400+ staff across Asia-Pacific and business development offices in the USA. CNS has more than 140 staff in Australia, New Zealand and the USA.

As part of the deal, clients can access leading services from both groups, including the CNS BioDesk, which provides early stage product development advice including toxicology, CMC and FDA/EMA regulatory consulting and interactions; and Novotech's advanced regional IT infrastructure, to support their clinical research programs.

Novotech CEO John Moller said:

"Biopharma clients should know this acquisition is a bringing together of the highest quality CROs in the region. Very importantly, we have developed remarkably similar company cultures, and I know the teams are excited about the opportunity of working together.

"Novotech and CNS will continue to operate under separate brands with CNS specialising in early phase non-oncology clinical trials across Australia and New Zealand, and Novotech specialising in regional Asia-Pacific and global project delivery across all phases.

"Our Asia-Pacific in-country relationships enable a comprehensive understanding of local regulatory requirements and changes, access to leading investigators, strong site connections, and accessible patient populations to deliver success for our clients within timelines and budgets."

CNS Managing Director Russ Neal commented:

"Early phase research in Australasia has seen incredible growth over the last 6-7 years and CNS is proud to be a significant part of this proven capability. As our clients have experienced success with us, we have often wished we had the international reach to continue supporting them.

"This truly complimentary association with Novotech now means that we are able to offer our clients access to Novotech's Asia-Pacific experience and expertise in later phase regional or global trials. On the other hand, Novotech clients can access our highly regarded global product development and regulatory affairs consultancy team, BioDesk, based out of Washington DC, London and Australia"

CNS COO and Executive Director Gabrielle McKee further added:

"CNS clients will also benefit from many of Novotech's strengths, including IT infrastructure and specialist functions such as legal, learning and development, marketing and analytics,. and particularly exciting, CNS and Novotech offer our clients one of the most experienced and knowledgeable biometrics teams in the region, with 70 staff in the combined unit."

About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia-Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia-Pacific presence includes running clinical trials in all key regional markets, with a worldwide reach through the company's network of strategic partners.

About Clinical Network Services (CNS) - https://clinical.net.au/
Clinical Network Services (CNS) is an integrated service group focused on product development. Headquartered in Australia, with offices in New Zealand, the UK and the USA, CNS creates value for small to medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

CNS offers a unique service, integrating BioDesk, an intelligent global product development and regulatory affairs consultancy, with its committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS' regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.

CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables it to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.

Media Contact:
Susan Fitzpatrick-Napier
communications@novotech-cro.com
USA: +1 415 951 3228
AUS: +61 2 8218 2144
ASIA: +65 3159 3427


Topic: Clinical Trial Results
Source: Novotech Health Holdings Pte Ltd / Clinical Network Services (CNS)

Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Novotech Health Holdings Pte Ltd Releated News
Sept 17, 2022 07:00 HKT/SGT
노보텍,제6회CGTWA 컨퍼런스에서‘2022세포유전자치료제우수상’수상
Sept 16, 2022 10:00 HKT/SGT
Novotech 在第六届细胞与基因治疗世界亚洲会议上荣获 2022 年细胞与基因卓越奖
Sept 16, 2022 10:00 HKT/SGT
Novotech 在第六屆細胞與基因治療世界亞洲會議上榮獲 2022 年細胞與基因卓越獎
Sept 15, 2022 17:00 HKT/SGT
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference
Sept 6, 2022 15:00 HKT/SGT
노보텍, 유럽종양학회 연례학술회의2022 참가 - 아태 지역 종양학 시험 부문 100 % 성장 기록한 새로운 데이터 공개
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575